On Wednesday, Danish authorities opted to ditch the coronavirus vaccine from Astrazeneca.
On this occasion, the Danish Health Authority gave the reason that the continued use of this vaccine is not worth the risk under the current circumstances, seeing as the infection rate is under control, and the majority of risk groups have been vaccinated.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.